Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TK2 | O00142 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL28320997 | 0.99 | TK1 (0.61) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL20268971 | 0.92 | TK1 (0.54) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL787593 | 0.91 | SLC28A1 (0.65) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL10382149 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL14596596 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL2722555 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12718344 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL767986 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL21078835 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12296879 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106967767-A | A kind of synthetic method of β thymidines | 苏州笃美生物科技有限公司 | 2017-07-21 | — | — | CN | disclosed |
| US-20120077866-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077862-A1 | ANTISENSE MODULATION OF PTP1B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120029049-A1 | Antisense Modulation of Superoxide Dismutase 1, Soluble Expression | Isis Corporation (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120022133-A1 | ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8101585-B2 | Reducing glucose levels, lipid levels or a combination thereof in a subject by administering a therapeutically effective amount of an antisense compound targeted to a JNK1 nucleic acid; treating metabolic syndrome, diabetes, obesity | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8093224-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2388318-A1 | Antisense modulation of connective tissue growth factor expression | Isis Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8039402-B2 | Methods for forming a gate and a shallow trench isolation region and for planarizating an etched surface of silicon substrate | SEMICONDUCTOR MANUFACTURING INTERNATIONAL (SHANGHAI) CORPORATION (CN) | 2011-10-18 | — | — | US | disclosed |
| EP-1660682-B1 | ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110039913-A1 | ANTISENSE MODULATION OF HYDROXYSTEROID 11-BETA DEHYDROGENASE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-7888324-B2 | Hybrid nucleic acids; controlling gene expression | GENZYME CORPORATION (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2280019-A1 | Antisense modulation of C-reactive protein expression | ISIS Pharmaceuticals, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-1325019-B1 | ANTISENSE MODULATION OF CLUSTERIN EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2272985-A1 | Antisense modulation of apolipoprotein (A) expression | ISIS Pharmaceuticals, Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2272958-A1 | Modulation of forkhead box O1A expression | ISIS Pharmaceuticals, Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2270024-A1 | Antisense modulation of superoxide dismutase 1, soluble expression | ISIS Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270231-A2 | Antisense modulation of insulin-like growth factor binding protein 5 expression | ISIS Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270230-A2 | Antisense modulation of insulin-like growth factor binding protein 5 expression | ISIS Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2003023011-A2 | ANTISENSE MODULATION OF RIBONUCLEASE L EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029049-A1 | Antisense Modulation of Superoxide Dismutase 1, Soluble Expression | SOD1, SOD3, RNASE1 | TK1 298/4885LMNA 3370/4885SMN1; SMN2 5/4885 |
| US-20120077862-A1 | ANTISENSE MODULATION OF PTP1B EXPRESSION | PPP3CA, PTPRJ, PPP2CA | TK1 144/4885LMNA 4107/4885SMN1; SMN2 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.